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Background: Databases of prescription drug purchases are now widely used in pharmacoepidemiologic studies.
Several methods have been used to generate drug use periods from drug purchases to investigate various aspects;
e.g., to study associations between exposure and outcome. Typically, such methods have been fairly simplistic, with
fixed assumptions of drug use pattern and or dose (for example, the assumed usage of 1 tablet per day). This paper
describes a novel PRE2DUP method that constructs drug use periods from purchase histories, and verified by a
validation based on an expert evaluation of the drug use periods generated by the method.
Methods: The PRE2DUP method is a novel approach based on mathematical modelling of personal drug
purchasing behaviors. The method uses a decision procedure that includes each person’s purchase history for each
ATC code, processed in a chronological order. The method constructs exposure time periods and estimates the
dose used during the period by considering the purchased amount in Defined Daily Doses (DDDs), which is
recorded in the prescription register database. This method takes account of stockpiling of drugs, personal
purchasing pattern; i.e., regularity of the purchases, and periods of hospital or nursing home care where drug use is
not recorded in the prescription register. The method can be applied to a variety of drug classes with different
doses and use patterns by controlling restriction parameters for each ATC class, or even each drug package. In the
presented example, the PRE2DUP method was applied to a register-based MEDALZ-2005 study cohort. All drug
purchases (3,793,085) recorded in the Finnish prescription register between 2002 and 2009 for persons with
Alzheimer’s disease (28,093) were included.
Results: Results of the expert-opinion based validation indicate that PRE2DUP method creates drug use periods
with a relatively high correctness. Drugs with varying patterns of use and drugs used on a short-term basis only
require more precise parameters.
Conclusions: PRE2DUP method gives highly accurate drug use periods for most drug classes, especially those
meant for long-term use.
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Starting from the 1990’s, electronic data on prescription
drug purchases have been collected in the Nordic countries
[1] and registers have been widely used in recent medical
research [2]. These registers enable the study of relation-
ships between drug exposure and outcomes, such as
hospitalization or death. When a research question re-
quires information on the duration of drug use, or the def-
inition of exposure status at a specific date, methods to
construct drug use periods from purchases are needed; i.e.,
when continuous drug use starts and ends. Currently, the
durations of drug purchases have been modeled with sim-
ple assumptions, such as the use of one Defined Daily Dose
(DDD) per day [3-6]. Some constants are often added to
the this duration (a grace period) or the purchased amount
has been multiplied with some factor to allow for lower ad-
herence, as prescribed medications are often taken at a rate
less than instructed [7]. Similarly, the assumption of one
tablet per day has been used to derive estimates for specific
drug use periods. Also, fixed time windows such as “pur-
chased a drug during last 90 days before the outcome date”
have been used as a proxy for current drug use [7-10].
These first generation methods may have serious weak-
nesses, which have been discussed by Tanskanen et al. [11].
Gislason et al. used personal, timely local dosages to esti-
mate refill lengths based on the number of dispensed tab-
lets [12,13]. This method is useful to identify personal
variations in dosages.
This paper describes a method that represents a new
approach to modelling drug exposure from register-
based data of drug purchases. The PRE2DUP method is
based on purchase histories and uses temporal dosages,
package information with refill time distributions and
patient’s personal purchase patterns. The basic idea of
the method is to simulate patient’s purchase behavior
and use this information to decide which purchases of a
particular drug belong to the same continuous drug use
period. The method has been under development since
2002, and it was first used by Tiihonen et al. in 2006
[14]. The present report describes the operation of ver-
sion 14, which has been applied to drug utilization re-
search since the spring of 2013 [15-18], and includes
results from an expert opinion based validation of the
drug use periods generated by the PRE2DUP method.
2 Methods
In the methods section, we describe the data source in sec-
tions 2.1-2.2, the functioning and calculations of the
PRE2DUP method in sections 2.3-2.8 and the validation of
the PRE2DUP method and statistical analyses in section 2.9.
2.1 Test cohort MEDALZ-2005
The MEDALZ-2005 (Medication use and Alzheimer’s
disease) study included all community-dwelling personsresiding in Finland with a verified Alzheimer’s disease (AD)
diagnosis and who were also still alive on December 31,
2005 (N = 28,093) [19]. Patients with AD were identified
from the Special Reimbursement Register. The Finnish
Special Reimbursement Register contains information
on reimbursement according to specific chronic diseases
such as diabetes, cardiovascular diseases and Alzheimer’s
disease. This data has been linked to the Prescription Regis-
ter, which includes data on all reimbursed prescription drug
purchases. Drugs used during hospital stays are not re-
corded in the register. Prescriptions purchased by the
Alzheimer patients, between 1.1.2002 and 31.12.2009, were
included in the study. This data has also been linked to the
hospital discharge register (Hilmo) and the long-term care
register. The hospital discharge register contains each per-
son’s identification number, the date of hospital admission,
diagnosis and eventual discharge of care. The long-term
care register contains the person’s identification number
and the starting date of care. Data from these registers is
collected with personal identification numbers, but only
de-identified data were used in this study. Thus, no ethics
committee approval was required. The test cohort was
chosen according to current research interests, and espe-
cially describes varying drug use patterns among older per-
sons with frequent hospitalizations.
2.2 Information content of the prescription register
The Finnish prescription register includes purchases of all
reimbursed prescription drugs within the entire country.
Data in the register includes purchase date, drug substance,
amount delivered in DDDs, Nordic Article number (vnr-
number), package size, number of packages and strength
of the drug, costs (EUR) and person identification num-
ber. Purchased drugs are coded according to the Ana-
tomical Therapeutic Chemical –classification system
(ATC) [5]. The vnr-numbers are included in the pre-
scription register for every purchase, and these numbers
were used to identify the drug package. The vnr-
numbers enable the identification of each different drug
package in terms of the number of tablets, strength,
manufacturer and dosage form. In the prescription
register, the purchased amount is also expressed in
DDDs, as a measure that can easily be transformed to
other units like milligrams or millilitres [5]. In Finland,
drugs may be dispensed for a maximum of 3 months’
treatment per purchase.
2.2.1 Pre-processing prescription register data
Since modelling is based on ATC codes and DDD
values, the prescription register data was pre-processed
to correct missing values in these variables. Some ATC
code changes were made during the years covered in our
data selection (2002–2009), and these were subsequently
corrected to the current ATC code. The same method
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remained without a DDD and/or a correct ATC code;
for example, some reimbursed lotions that do not have
any ATC code or DDD value. After these corrections,
the purchases for each person and each ATC code were
processed to chronological order.
2.3 Drug use periods, the output
The output of the method is a set of drug use periods. A
drug use period is a time span describing continuous use
of a certain drug (ATC code) and, thus, describes the
time period when a person has used a drug. A drug use
period consists of start date, end date, person id, ATC
code, amount of purchased DDD, number of hospital
days, number of purchases, and average DDD per day
dose. Drug use period(s) are constructed for every per-
son and for each ATC code the person has purchased.
Drug use periods are timely non-overlapping for each
person and each ATC code, so switching from one prod-
uct to another within the same ATC code is coded as
one drug use period. A person may have multiple drug
use periods for the same ATC code if there is a break in
purchases, so that it is not possible for a drug to have
remained from one purchase to the next. A drug use
period may include one or more purchases. The average
dose of a drug use period is modelled as the average
DDD per day, as the purchased amount is recorded as
DDDs in the prescription register, and is independent of
changes in units (grams, milligrams, micrograms etc.).
2.4 Overall functioning of prescriptions to drug use
periods (PRE2DUP) method
PRE2DUP is based on modelling of personal drug pur-
chasing behavior. PRE2DUP method uses a decision pro-
cedure where each person’s all purchases of one ATC
code are processed in a chronological order. The method
is based on temporal averages of daily dose that are used
to calculate the expected refill time to next purchase.
The overall system is shown in Figure 1. Initially, one
defines a set of parameters for the ATC classes and drug
packages (defined with vnr-numbers). Next, the prepro-
cessing phase of the method generates temporal aver-
ages and statistics describing the regularity of each
person’s purchase histories for each ATC code. After
the preprocessing phase, PRE2DUP calculates the drug
use periods based on drug purchases, hospital days and
regularity statistics drawn from the data. The core pro-
cedure refers to calculations of drug use periods (Figure 2).
Hospital days are excluded from drug use periods in
this calculus. We use this exclusion for dosage calcula-
tions, not for splitting drug use periods due to short
hospital stays. Exclusion of hospital stays does not
imply that drug use period would stop and produce a
gap to each hospitalization.After the core has run for the first time, the method
calculates refill length distribution for each vnr-number.
The most common refill length is extracted from the
distribution data and used when the core is run again.
The most common refill length is assigned as the typical
duration for a single purchase when there is no other in-
formation for the duration of drug use. This iteration
process is run until the results are stable. These itera-
tions may also include redefining the expert-defined par-
ameter sets.
2.5 Expert-defined parameters
To use the PRE2DUP method, parameters for dosage
limits, hospital stays and maximum refill times were formu-
lated. These parameters restrict the joining of purchases
over unrealistically long time periods (i.e., long hospital
stays and drug use with doses that are too low to be realis-
tic). Such parameters reflect, for example, reimbursement
regulations and dispensing practices, which may be differ
between countries. These parameters may need redefining
after the first iterations of the method. The hierarchy of pa-
rameters are from specific to global, and vnr (package) pa-
rameters override ATC class parameters.
2.5.1 Global parameters
Following global parameters apply to all purchases. The
maximum refill time used in sliding temporal average
calculations was set to 300 days. The maximum hospital
stay, included as the last purchase in a drug use period,
was set to 30 days. This prevents extending the drug use
period over a long hospital stay. The maximum DDD
per day was limited to 10, to limit possible variations
when two purchases are only one or even a few days
apart. Maximum length of a single purchase was set to
150 days, regardless of the purchased DDD amount. Dif-
ferent parameter values have been tested like 120, 150
and 180 days for single purchase or 270, 300 and
330 days for maximum refill time in sliding temporal
average calculus to find a compromise for different
drugs. Global parameters cannot be overridden by other
parameters.
2.5.2 ATC class parameters
The parameters defined for ATC classes can be defined
hierarchically, starting from the main level and progres-
sing towards finer sub-levels. The method uses for each
purchase the finest level that has been defined. This is
useful when some drugs in the same main ATC class are
used very differently. The parameters for ATC classes in-
clude lower limits for the daily dose, the common daily
dose (as DDD), the minimum length of a drug use
period (days) and the maximum refill length (days)
allowed in continuous use. The lower limit for daily dose
guides the PRE2DUP to split drug use periods, if the
Figure 1 The overall operation of PRE2DUP. Data is first preprocessed, and then drug use periods are calculated. New parameters are
calculated iteratively, to improve the results. Green arrows show the work-flow around the core process. Red numbers link to particular sections
in the text.
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the cut-off was set relatively low for many ATC classes,
due to the advanced age of the cohort, yet higher cut-
offs could be used for different (e.g., younger) patient
groups. The common daily dose is used when there is
no better estimate for refill time length. We defined a
total of 174 ATC parameters on different levels of the
classification (Table 1).
2.5.3 Vnr-parameters
The idea of using vnr-parameters is to define upper and
lower limits for the refill length of each drug package
(identified by vnr-number), and these values represent
the finest level of expert-defined parameters. These
values are based on the pharmaceutical properties of the
drug in terms of dosage form, the assumed pattern of
use, longevity after opening and the number of divisibleunits. Vnr-parameters include minimum refill length,
maximum refill length, typical refill length and corre-
sponding DDD per day values. Maximum refill length
for a package is based on the number of included units
(e.g.; tablets, capsules, injections), how they dividable
and how often this drug has to be taken (e.g.; once a
day, once a week, etc.). For example, a package contain-
ing 30 non-dividable capsules for a drug taken once
daily, the vnr-parameter for maximum refill length may
be set to 30 days (or to allow some non-adherence, for
example 1.2 ×30 days). Minimum refill length may be
set to 15 days if 2 capsules per day represent the max-
imum dose per day. A typical refill length would be
30 days. We defined the vnr-parameters for 2226 pack-
ages based on the current research interests, and in-
cluded mainly ATC classes, such as N (Nervous system)
and M (Musculo-skeletal system) (Table 1).
Figure 2 The work-flow of the core process. Red arrows illustrate the retrieval of a person’s next purchase of the same ATC code. The blue
background marks the processing of a person’s single purchase of an ATC code. The green background shows the processing of stockpiling. Red
numbers link to particular sections in the text. Thin arrows present dataflow, bold arrows logic.
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Table 1 The number of expert-defined parameters in each
ATC class






A: Alimentary tract and metabolism 31 354
B: Blood and blood forming organs 10 74
C: Cardiovascular system 13
D: Dermatological drugs 12
G: Genitourinary system and
reproductive hormones
8 43








M: Musculoskeletal system 12 519




R: Respiratory system 13
S: Sensory organs 15
V: Various ATC structures 22
Total 174 2226
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The preprocessing phase calculates variables that are
used by the core process and do not change during iter-
ations. Preprocessing calculates refill times between each
person’s purchases of one ATC code, the number of hos-
pital days between purchases, temporal averages of daily
doses as DDD per day, referred as DDDAVG, and vari-
ation of the daily dose (i.e., the coefficient of variation
for DDDAVG, referred as DDDAVGcv).
2.6.1 Temporal average
For each purchase, a sliding weighted temporal average
for dose (DDDAVGi) is calculated from each persons’
subsequent purchases of the same ATC class as follows:
DDDAVG i ¼ DDDi−1 þ 4DDDi þ DDDiþ1Ti−1 þ 4Ti þ Tiþ1 ð1Þ
where DDDi is the DDD amount that is purchased at
time i, and Ti is the number of days between purchase i
and i + 1. The consecutive drug purchases are weighted
with weights of one, four and one for i-1, i and i + 1 re-
spectively. Weights were selected to give high weight for
current purchase and equal weights for previous and
next purchase. For each person’s first purchase of each
ATC-code, DDD amount and time weights are five for i,
one for i + 1, and for the last purchase one for i-1 and
five for i. For the last purchase i, Ti is calculated fromthe previous purchase while assuming the same DDD per
day value as the previous purchase, Ti = DDDi/(DDDi-1/
Ti-1). The assumption that dose does not change is used for
convenience. When the time between two purchases is over
the maximum refill time (300 days), it is assumed that they
do not belong in the same treatment period, and thus, the
DDDAVG calculus is ended and restarted after this time
gap. Average DDDs per day are only calculated when
there are at least three purchases of the same ATC code
for one person. When there are less than three pur-
chases of an ATC code, such purchases are collectively
transferred to the core process without pre-processing.
Hospital days are excluded (i.e., days in hospital have
been subtracted from T).
2.6.2 Coefficient of variation for DDDAVG
The coefficient of variation for DDDAVG (DDDAVGcv)
describes the regularity of a purchase pattern, and is cal-
culated for each patient and for each ATC code, where
DDDAVGcv is the standard deviation of DDDAVG di-
vided by the mean of DDDAVG. The coefficient of vari-
ation is large if there are a lot of variations in refill times
Ti and/or purchased DDDi. The coefficient of variation
for DDDAVG is calculated when DDDAVG is calculated
for a particular ATC code (i.e., when there are more
than two purchases of the same ATC code and the pur-
chased amount is recorded in DDDs).
2.7 Package refill lengths
Distributions of package refill lengths are calculated for
each vnr-number, in order to define the most common
refill time length in the study population. When the core
of the model has run for the first time, a new parameter
space is generated for package refill lengths. The distri-
butions of refill lengths are calculated from drug use pe-
riods that include the particular package (identified by
vnr-number) for each vnr-number. This is done by join-
ing together the number of refill lengths to the nearest
local maximum. From these refill length distributions we
selected a mode to present the expected refill length for
each package. Only modes having more than a threshold
value of purchases are used, and the threshold was set to
10 purchases. We included only drug use periods that
had at least six purchases to calculate the refill lengths
for each package. These drug use periods may also in-
clude purchases of other packages (other vnr-numbers),
but purchases including multiples of different packages
are not used, as to avoid problems with multiple
strength dosages. The refill lengths are used as such
without subtracting hospital stays. Purchases dispensed
as a dose dispensing service were not included in the
calculation of refill lengths, as the whole package is not
dispensed to one person in such cases. Figure 3 shows a
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Figure 3 Refill length distribution of simvastatin (vnr 010940, 10 mg, 98 tablets, ATC C10AA01). The most common refill length (98 days)
is the number of tablets in the package, which corresponds to a dosage of 0.33 DDD per day (as 1 tablet per day). Black bars are the original refill
times and brownish bars joined ones.
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processed refill length distributions (black bars), the peak
is at 98 days (14 weeks) with 692 purchases, and after join-
ing the refill time lengths to the nearest local maximum,
the peak then includes 2718 purchases (brownish bars).
Sometimes joining produces a different peak time than the
highest peak in the original distribution.
2.8 Calculation of drug use periods, the core process
Figure 2 shows the core of the algorithm, where the de-
cision is made to determine which consecutive pur-
chases belongs to the same drug use period. When this
core is run for the first time, it has no method-generated
parameters (such as package refill lengths), and uses only
expert-defined parameters (section 2.5). In the following
runs, expert-defined parameters for typical refill lengths
are overrun when there are enough purchases of a pack-
age in question, typically hundreds of purchases, so that
refill time lengths may be calculated from the data.
The calculation of drug use periods differ for single
purchases, when there is no joining procedure and no
personal purchase history for the ATC code in question.
When a purchase history includes more than two pur-
chases of the same ATC code, we primarily use the per-
son’s own purchase history, secondly package (vnr)
parameters and thirdly the ATC class parameters. Even
if a person has more than one purchase for certain ATC
code, some purchases are treated in this process as sin-
gle purchases if they are far away from each other in
time. For single purchases, PRE2DUP uses information
gathered from other persons’ purchases of a particular
drug package (package refill lengths, see 2.7). If a person
has two purchases of an ATC code, the core proceduretests to see if these two purchases are not too far apart
to be joined into same drug use period, and this is done
with vnr- and ATC parameters.
2.8.1 Single purchase
If a patient has only one purchase of a certain ATC code,
the model uses the most common refill length for the
purchased package in the study population (see sec-
tion 2.7). The length of drug use period is the typical re-
fill length multiplied with the number of purchased
packages. If the most common refill length is not available,
due to a rarity of purchases of the package, the expert-
defined typical DDD per day value for this package or ATC
class is used to calculate the length of drug use period. The
length is calculated as [purchased DDD(1 +DDD constant
for non-perfect adherence =0.2)]/recommended DDD per
day. However, the maximum length for a single purchase
was limited to 150 days.
If a person has a purchase that is modelled as a separ-
ate drug use period, and some longer drug use periods
of the same ATC code (for example two years apart), the
DDD per day for the single purchase is adopted from
the person’s nearest drug use period having at least two
purchases.
If refill time length of the package in the study popula-
tion and purchased amount in DDD are missing, then
the ATC class-defined minimum length for drug use
period is used.
2.8.2 Connecting purchases
When person has more than one purchase of one ATC
code, the method evaluates consecutive purchases to
form drug use periods. The process utilizes data from
Table 2 An example of purchase history, consisting of
five purchases; each of 10 DDDs and average dose is one
DDD per day
Purchase i 1 2 3 4 5
DDD 10 10 10 10 10
Days between i and i + 1 10 5 15 10 NA
DDD per day to next purchase 1,00 2,00 0,67 1,00 NA
Sliding temporal average DDDAVGi 1,09 1,33 0,80 0,92 1,00
Calculated refill time length in days 9,17 7,50 12,50 10,83 10,00
The second purchase shows a possible example of stockpiling and the third
purchase suggests the use of this stock.
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processing phase of the method. The connection is made
if the purchased amount is calculated to last until the
next purchase.
2.8.2.1 Expected refill length The PRE2DUP algorithm
connects purchases based on the local DDDAVGi value
for purchase i.
The expected refill length of purchase i is referred to
as ERFLi, which is calculated as follows:
ERFLi ¼ DDDi  1þ DVAR DDDAVGcvð ÞDDDAVGi ð2Þ
Where DDDi is purchased amount, 1 + DVAR*DD-
DAVGcv is a multiplier that reflects a persons’ regular-
ity of purchases, and DVAR is set to 0.5. Thus, 50% of
the coefficient of variation is added to the multiplier.
The DDDAVGi value is compared to the lower limit of
DDD per day that is set for the purchased package
(section 2.5.3), or when no vnr-parameter is available
the DDDAVGi that is set to the lower limit of the ATC
class (section 2.5.2).
If the DDDAVGi is lower than the preset ATC lower
limit, it means that the next purchase is further away
than the regular drug use pattern this drug would allow,
and the algorithm uses package refill length to calculate
the duration of the purchase and the drug use period is
ended after this purchase. If the refill length for this
package is not available, the algorithm uses the common
DDD per day of the ATC class when the purchased
amount is recorded in DDDs. In a rare case, when a
DDD value is missing, the algorithm uses expert-
defined refill length for this ATC class. ERFLi is thus lim-
ited according to the package and ATC parameters, in
order to avoid unrealistically long refill lengths. This is done
to limit ERFLi in cases of large stockpiling, irregular use of
a drug (take “when needed”) or a restart of drug use after a
long break. This limiting process truncates drug use period
according to common continuous use pattern.
If the DDDAVGi exceeds a preset upper limit for daily
dose, we use the limit instead of DDDAVGi for deter-
mining the length of the purchase period. This may hap-
pen when purchases are only one or a few days apart.
If the current purchase happens to be the last one for
an ATC code the drug use period ends and algorithm
starts to process the person’s purchases of the next ATC
code. If there are more purchases of this particular ATC
code, the algorithm tests whether or not the calculated
refill length for this purchase reaches the next purchase.
If it reaches the next purchase, the algorithm starts to
process the next purchase. If a calculated refill length is
shorter than the time until the next purchase, themethod tests whether or not there has been stockpiling
before the current purchase.2.8.2.2 Stockpiling test The stockpiling test compares
DDDAVGi with the DDDAVG of the previous purchase
(DDDAVGi-1) and the following purchase (DDDAVGi+1).
The rationale for this test is that changes in the sliding
temporal average over three subsequent purchases is in-
sufficient to take stockpiling into account. A simple ex-
ample, presented in Table 2, describes the function of
this test. In this example, the second purchase represents
possible stockpiling (i.e., short intervals between purchases)
and the third purchase represents the use of this stock (i.e.,
long intervals between purchases). The DDDAVG3 is 0.8
and this gives a calculated refill time of 12.5 days. Here, the
DDDAVG3 is lower than DDDAVG2 and DDDAVG4.
Thus, the drug use period continues over this interval.
If the DDDAVGi is not lower than the previous
DDDAVGi-1, or the following DDDAVGi+1, then the drug
use period ends and is entered into the drug use period
set. If the DDDAVGi is lower than the previous and the
following DDDAVG values, then the algorithm calculates
a refill time length with the current and previous pur-
chases taken together, as described above for one purchase
(section 2.8.2.1). This means that the refill length is calcu-
lated as two subsequent purchases, which would have
happened at the time of the first purchase. If the calcu-
lated refill length for these two purchases (taken together)
reaches the next purchase, then algorithm starts to process
next purchase; i.e., the drug use period continues. Other-
wise the current drug use period ends.2.8.3 Calculating the length of a drug use period from the
last purchase
The end of a drug use period is calculated from the last
purchase. When a drug use period contains more than
one purchase, the algorithm uses the purchased DDD of
the last purchase at datei, so that the DDDAVGi and the
number of purchases belong to this drug’s use period
(denoted by k, in Equation 3):
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the last purchase i as
END ¼ datei
þ DDDi  1þ 0:5 DDDAVGcvð Þ
DDDAVGi  1þ e−kð Þ
þ HDi ð3Þ
where coefficient 1 + e-k limits stockpiling for periods
with very few purchases. HDi is the number of hospital
days that fall within the calculated time after the last
purchase that is added to the drug use period. If the per-
son is hospitalized before the drug supply of the last
purchase ends, the number of hospital days is added to
the length of the last purchase as long as there is no
continuous hospital stay exceeding the predefined limit
(in our example, 30 days).
If there is no data on purchased DDDi or no DDDAVGi,
then the duration of the last purchase is calculated as in
case of single purchase, but using the last purchase instead
of the first (only). This case applies only when there are
two purchases of this ATC code for one person, or when
the purchased amount in DDD is not registered.
2.9 Validation of the results produced by PRE2DUP
The validity of calculating drug use periods produced by
the PRE2DUP method was assessed by two independent
reviewers with expertise in clinical pharmacy (HT and
MK). We did two separate validations; one with pur-
chases (referred as the purchase test) and another with
drug use periods (referred as the drug use period test).
In the purchase test, we randomly selected 1000 pur-
chases and rated them as correctly placed in a drug use
period (i.e., single purchase period, included in a correct
drug use period or being either the end or the beginning
of a period). Purchases that lacked sufficient information
for making a decision (e.g., no DDD or package informa-
tion) were classified as non-solvable. The classes were
correct, wrong and non-solvable.
In the drug use period test, we randomly selected 1000
drug use periods to determine if they included the correct
set of purchases, or not. This means that the first purchase
was correct, the subsequent purchases belonged to this
drug use period and the last purchase correctly ended the
period. In addition, possible purchases after the last one
and before the first in the drug use period were also evalu-
ated, to determine of if they should have belonged to the
drug use period, or not. In this case, the logical options
were; 1) the drug use period consisted of correct purchases,
2) the drug use period was incorrectly generated (i.e., the
start or end of the purchase period was incorrect, or it
should be divided into two or more periods), 3) there was
not enough information to judge correctness. In the pres-
entation of the results for both tests, we defined the“correct” option when at least one of the reviewers stated
the purchase or drug use period as correct, and “error”
when both reviewers agreed that it was erroneous, and the
rest as “non-solvable”. To assess the reliability of the two
expert opinions, we used Krippendorffs alpha (K-alpha)
[20] to measure of how each reviewer’s opinions matched
with each other.
The PRE2DUP method has been implemented with
dBase 2.8 (dBase LLC, Binghampton, NY). Statistical
analyses were performed with SPSS version 22 (IBM
corp., Armonk, NY).3 Results
3.1 Drug use periods
PRE2DUP generated 703,839 drug use periods from
3,793,085 purchases. The total number of purchased
DDDs was 250 million, with a total drug use period
length of 0.89 million years. The mean length of a drug
use period was 458 days, and the total length was
31 years per person. This implies a high rate of poly-
pharmacy during a seven year follow-up time. There
were 9,583 purchases without an ATC code in the data.
The longest mean durations were found in ATC classes
C (Cardiovascular system) and L (Antineoplastic and
immunomodulating agents); 864 and 778 days, respect-
ively (Table 3). These ATC classes also had the highest
DDD amounts per drug use period, with medians of 335
(ATC class C) and 300 (ATC class L). Drugs in these
ATC classes are mostly for continuous use. The shortest
median duration was in ATC class P (Antiparasitic prod-
ucts), where the drug use periods mostly had a single
purchase, and thus did not include enough information
to count typical refill times. In this case, the median
length of drug use was 15 days, which was the preset
minimum length for a drug use period. The average
DDD per day was higher than the median for all ATC
classes except G; which implies a skewed distribution.
The group OTHER was a mixture of ATC classes that
lack DDD values (e.g., ATC classes D for Dermatologi-
cals, S for Sensory organs [mostly eye and ear drops]
and V for Various).3.2 Validity of drug use periods
Two independent reviewers evaluated whether or not
purchases were correctly placed in drug use periods, and
results of the purchase test are shown in Table 4. Both
reviewers judged 87% (N = 867) of the examples as cor-
rect and 4% (N = 39) as erroneous. The proportion of
purchases that at least one of the reviewers had judged
as correct was 92%. The amount of non-solvable cases
was 5% and 4% for the reviewers MK and HT, respect-
ively. The reliability between reviewers opinions, as mea-
sured by Krippendorffs alpha, was 0.67 (95% Cl 0.5,
Table 3 Purchases and drug use periods by ATC class among persons with Alzheimer’s disease in the MEDALZ-2005
data during years 2002-2009
ATC
CLASS
Purchases Drug use periods
N N Number of purchases per drug use period DDD of drug use period Length in days DDD per day
Median Mean Median Sum Median Mean Median Mean
A 402,210 82,735 2 5 100 3,2475,207 150 418 0.85 1.00
B 116,233 19,422 3 6 200 7848,540 351 638 0.64 0.87
C 1,075,095 124,811 5 9 300 8,6698,771 573 864 0.60 0.78
G 130,913 21,662 3 6 133 8886,697 241 529 0.78 0.78
H 86,325 14,297 3 6 133 5062,266 253 615 0.60 0.76
J 155,495 94,577 1 2 8 2040,569 21 106 0.33 0.38
L 17,547 2,061 6 9 335 1308,533 566 778 0.80 0.81
M 202,855 70,855 1 3 33 1,0474,142 50 197 0.75 0.77
N 1,328,357 173,702 4 8 140 8,3409,222 320 596 0.68 0.75
P 3,445 1,366 1 3 6 95,713 15 217 0.40 0.42
R 117,953 29,594 1 4 64 7443,245 138 349 0.67 0.74
OTHER 156,657 68,757 1 2 0 5085,132 28 147 0.00 0.11
TOTAL 3,793,085 703,839 250,828,037
PRE2DUP created 703,839 drug use periods from 3,793,085 purchases. The total number of purchased DDDs was 250,828,037. OTHER included ATC classes D, S
and V. The common names of ATC classes are found in Table 1.
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was 65 (6.5%) for all purchases.
The drug use period test evaluated if the drug use pe-
riods included the correct set of purchases, or not. Both
reviewers judged that 64% (N = 635) of the drug use pe-
riods were correct and 8% (N = 84) were erroneous
(Table 5). The inter-reviewer Krippendorff alpha was
0.66 (95% CI 0.54, 0.78).
The validity of the PRE2DUP methods varied between
different ATC classes. The best results for the purchase
test were achieved for ATC classes A, B, C, G, N and R,
where the rate of correct placements was over 90%
(Table 6). This was measured so that at least one of the
two reviewers judged it correct. Error rates were high
for ATC classes H and J and in the group described as
“OTHER” (i.e.; ATC D, L, P, S and V), where there were
a remarkable proportion of non-solvable cases. When
comparing the performance against the number of
expert-defined parameters we can see that there were noTable 4 Reviewers’ judgments on the correctness of
placing a purchase in a correct drug use period (purchase
test)
Purchases Reviewer HT Total
Correct Error Not Solvable
Reviewer Correct 867 17 7 891
MK Error 16 39 2 57
Not Solvable 14 9 29 52
Total 897 65 38 1000vnr-parameters for ATC class J and H and the group
“OTHER” (Table 1).
The rate of correct drug use periods was lower in the
drug use period test than in the results of the purchase
test. ATC classes A, B, and N had correctness rates over
90% and G and M over 80% (Table 7). High error rates
were found to be over 10% in ATC classes G, H, J and R.
The amount of non-solvable drug use periods was ex-
tremely high in the group described as “OTHER” (63%),
which was caused by the lack of DDDs in this data. The
average performance of the method was fairly high, as
79% of all drug use periods were classified as correct
and only 8% erroneous. Especially for the ATC class N,
which had a high correctness rate, and this was achieved
with comprehensive vnr-parameters (Table 1).
4 Discussion
PRE2DUP is based on modelling of drug purchasing be-
havior, and it creates drug use periods with high preci-
sion. The results of the validation show that with aTable 5 Reviewers’ judgments on the correctness of drug
use periods (drug use period test)
Periods Reviewer HT Total
Correct Error Not Solvable
Reviewer MK Correct 635 36 10 681
Error 82 84 2 168
Not Solvable 23 4 124 151
Total 740 124 136 1000
Table 6 Distribution of reviewer judgments by ATC classes in the purchase test, which measured correct purchases in




Correct Error Non solvable Correct Error Non solvable
ATC class A 89 2 1 92 97 2 1
B 44 0 0 44 100 0 0
C 275 2 13 290 95 1 4
G 37 1 0 38 97 3 0
H 21 6 1 28 75 21 4
J 28 12 0 40 70 30 0
M 46 5 4 55 84 9 7
N 325 8 4 337 96 2 1
R 32 2 1 35 91 6 3
OTHER 24 1 16 41 59 2 39
Total 921 39 40 1000 92 4 4
The category “OTHER” included classes D, L, P, S and V. These have been combined, due to the low numbers of purchases and poor data quality (high proportion
of missing DDD values). The common names of ATC classes are found in Table 1.
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able solutions. The correctness of estimating the drug
use periods depends on how precisely the parameters
are defined. The most accurate results are gained with
the parameterization of drug packages through vnr-
numbers. Results show that the method calculates correct
drug use periods with very few expert-defined parameters
for drugs that have a regular use pattern. Drugs that tend
to have a varying pattern of use (i.e., multiple indications
with different dosage ranges, for example antipsychotics),
and for drugs that are only used on a short-term basis
(such as antibiotics), or with seasonal variation patterns
that require more precise parameters.Table 7 Distribution of reviewer judgments by ATC classes on
Classification
Correct Error Not solva
ATC class A 117 7 5
B 24 2 0
C 135 4 34
G 32 7 0
H 11 6 1
J 104 43 0
M 77 3 12
N 217 5 2
R 31 5 9
OTHER 38 2 67
Total 786 84 130
The category “OTHER” included classes D, L, P, S and V. These have been combined
of missing DDD values). The common names of ATC classes are found in Table 1.The low value of Krippendorffs alpha in the drug use
period test needs some clarifications. The rates of erro-
neous and non-solvable drug use periods were higher in
the drug use period test than in the purchase test. This
may be due to the multiple judgments that have to be
made when there are multiple purchases in the evalu-
ation of the drug use period test. Further, the distribu-
tions of ATC classes that were randomly selected for
validation were different in the two validation sets,
which may also affect the results. The likelihood to be
randomly selected for the purchase test was high when
the number of purchases per ATC class was also high.
The likelihood to be randomly selected for drug usethe correctness of drug use periods
Total %
ble Correct Error Not solvable
129 91 5 4
26 92 8 0
173 78 2 20
39 82 18 0
18 61 33 6
147 71 29 0
92 84 3 13
224 97 2 1
45 69 11 20
107 36 2 63
1000 79 8 13
, due to the low numbers of purchases and poor data quality (high proportion
Tanskanen et al. BMC Medical Informatics and Decision Making  (2015) 15:21 Page 12 of 13period test was high when the number of drug use pe-
riods per ATC class was high (and, subsequently low
when the number of drug use periods was also low,
which may indicate long and continuous drug use pe-
riods). The number of purchases included in the period
affects the correctness of the drug use period, because a
decision of correctness is made for every purchase in
turn. Thus, it is proportional to the product of single de-
cisions for correctness of all purchases in the drug use
period. It is also important to remember that erroneous
results in validation are not necessarily completely
wrong, and erroneous can also mean that a drug use
period was one week too long after the last purchase, or
two purchases were joined over a time gap that both re-
viewers judged to be two weeks too long.
The PRE2DUP method is more flexible than previous
methods that are mostly based on simple assumptions,
such as one tablet per day or one DDD per day, and has
several advantages over such first generation methods
[11]. Most importantly, PRE2DUP uses personal pur-
chase histories with no single fixed dosage assumptions,
and both dosage and purchase patterns are calculated
individually for each person and each drug. Thus, it pro-
duces a better estimate of an actual drug use pattern
with the consideration of natural variations in usage for
each person. Secondly, PRE2DUP effectively utilizes
package information, both through expert-defined pa-
rameters and through parameters calculated from pur-
chase histories (i.e., package refill lengths). This produces a
set of reliable parameters that match with actual drug use
patterns in a particular study population, instead of relying
on manufacturers’ instructions or other assumptions.
Thirdly, the PRE2DUP can be guided to more optimal re-
sults through its recursive nature, and it is possible to target
fine-tuning towards problematic drug classes, or even the
use of single packages. Fourthly, it can be adapted to differ-
ent levels of information. For example, if there is no pack-
age information available, the sub-routines using package
information are not used and the method only uses pur-
chased DDD values and ATC class parameters.
The vast parameter space may be difficult to control, and
anomalies may exist if there are very different subpopula-
tions. To solve this problem, we treated patient cases and
their controls separately in the MEDALZ-2005 study, be-
cause the cases have the diagnoses of Alzheimer’s disease,
whereas controls did not. It may sometimes also be useful
to split a population, for example according to age, and
then process drug use separately for children, adults and
older persons.
We have not dealt with the question of how long differ-
ent drugs remain in body after the end of a drug use period.
This is one thing that could be added to the calculus for
some specific drug classes. However, there is no data on
drug use after the last purchase, and purchased stock is notalways used completely. Dealing with long elimination half-
lives of drugs after the last purchase may require informa-
tion on gender and age, which are routinely available from
the registers, but possibly also the weight of the patient is
required, which is rarely available.
The PRE2DUP method is evolving and new features
are added according to the needs that may arise from
various research questions, population characteristics or
content of the registers. Our goal is to make the method
as data driven as possible; i.e., minimize manual tuning
and parameterization. In this effort, we have presented a
method to convert drug purchases to drug use periods. We
hope that it leads to the development of new methods and
improvements in register-based pharmacoepidemiology.
We presented the application of PRE2DUP method to
a specific population (persons with Alzheimer’s disease).
The population is characterized by a high number of co-
morbidities, concomitant drugs and frequent hospitaliza-
tions and thus, it represents ultimate challenge to
modelling of drug use. However, these characteristics are
not requirements for this method. We have used earlier
simpler versions of this method with persons with men-
tal disorders and ATC N group drugs [14,21,22] and we
also have applied the method for drug purchases of
matched controls without Alzheimer’s disease in this
data. A limitation is that we tested the method only to
Finnish data and Finnish prescription and dispensing
regulations. We have not compared the drug use periods
produced by the PRE2DUP with other methods in this
study. The strengths of this study are large prescription
data with long follow-up time, and ability to model use
of all different drug groups with various patterns of use.
We do not know any other studies, where large pre-
scription dataset with all different drugs used (over 700
different ATC codes) by large population (over 50 000
persons together) has been modelled with a single
method. Previous studies have concentrated on one or a
couple of related drugs and methods have been tailored
for these particular cases. The strength of PRE2DUP is
that it treats all patients and drugs individually and pos-
sible bias in timing of drug exposure is not linked to
predefined dosage (DDDs or tablets) nor to regularity of
purchases (fixed time windows). This is very important
when the outcomes are related to dosage or adherence
and bias in calculated drug exposure is larger with atyp-
ical drug use than in common drug use.
5 Conclusions
Previously, drug use periods have been calculated with fixed
assumptions of dosage and refill length. These methods do
not take into account personal dosage, dosage changes over
time or differences in purchase behavior and may lead to
incorrect results. PRE2DUP method uses personal drug
purchase histories and fits parameters for each person and
Tanskanen et al. BMC Medical Informatics and Decision Making  (2015) 15:21 Page 13 of 13drug. It uses package information effectively and produces
highly correct estimates for drug use periods for most drug
classes.
Studies comparing different ways to convert prescrip-
tion data to drug use periods are needed in different set-
tings (patient groups, drugs and countries). With these
comparative studies researchers can choose the best
method or develop new ones for their own settings.
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